High performance plasma amyloid-β biomarkers for Alzheimer’s disease

Nature, Journal Year: 2018, Volume and Issue: 554(7691), P. 249 - 254

Published: Jan. 31, 2018

Language: Английский

---

Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic

Nature Reviews Neurology, Journal Year: 2018, Volume and Issue: 14(11), P. 639 - 652

Published: Oct. 8, 2018

Language: Английский

---

Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

Alzheimer s & Dementia, Journal Year: 2018, Volume and Issue: 14(8), P. 989 - 997

Published: April 4, 2018

Abstract Introduction We examined and compared plasma phospho‐tau181 (pTau181) total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, cortical thickness; (3) as a screening tool for elevated Aβ. Methods Participants included 172 cognitively unimpaired, 57 mild impaired, 40 AD dementia patients with concurrent Aβ PET (Pittsburgh compound B), (AV1451), magnetic resonance imaging, tau, pTau181. Results Plasma pTau181 levels were higher than those unimpaired. was more strongly associated both PET. sensitive specific predictor of good as, or better than, combination age apolipoprotein E ( APOE ). Discussion may have utility biomarker pathophysiology noninvasive screener

Language: Английский

---

Current state of Alzheimer’s fluid biomarkers

Acta Neuropathologica, Journal Year: 2018, Volume and Issue: 136(6), P. 821 - 853

Published: Nov. 28, 2018

Alzheimer's disease (AD) is a progressive neurodegenerative with complex and heterogeneous pathophysiology. The number of people living AD predicted to increase; however, there are no disease-modifying therapies currently available none have been successful in late-stage clinical trials. Fluid biomarkers measured cerebrospinal fluid (CSF) or blood hold promise for enabling more effective drug development establishing personalized medicine approach diagnosis treatment. Biomarkers used programmes should be qualified specific context use (COU). These COUs include, but not limited to, subject/patient selection, assessment state and/or prognosis, mechanism action, dose optimization, response monitoring, efficacy maximization, toxicity/adverse reactions identification minimization. core CSF Aβ42, t-tau, p-tau recognized by research guidelines their diagnostic utility being considered qualification subject selection However, need better understand potential other COUs, as well identify additional reflecting aspects Several novel proposed, role pathology yet validated. In this review, we summarize some the pathological mechanisms implicated sporadic highlight data several established (including BACE1, TREM2, YKL-40, IP-10, neurogranin, SNAP-25, synaptotagmin, α-synuclein, TDP-43, ferritin, VILIP-1, NF-L) associated each mechanism. We discuss biomarker.

Language: Английский

---

Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021

The Journal of Prevention of Alzheimer s Disease, Journal Year: 2021, Volume and Issue: unknown, P. 1 - 16

Published: Jan. 1, 2021

Alzheimer’s disease is a progressive, irreversible neurodegenerative impacting cognition, function, and behavior. progresses along continuum from preclinical disease, to mild cognitive and/or behavioral impairment then dementia. Recently, clinicians have been encouraged diagnose earlier, before patients progressed The early accurate detection of disease-associated symptoms underlying pathology by fundamental for the screening, diagnosis, subsequent management patients. It also enables their caregivers plan future make appropriate lifestyle changes that could help maintain quality life longer. Unfortunately, detecting early-stage in clinical practice can be challenging hindered several barriers including constraints on clinicians’ time, difficulty accurately diagnosing pathology, healthcare providers often dismiss as part normal aging process. As prevalence this continues grow, current model diagnosis patient will need evolve integrate care across disciplines continuum, beginning with primary care. This review summarizes importance establishing an related practical ‘how-to’ guidance considerations, tools used throughout diagnostic journey.

Language: Английский

---

Blood-based biomarkers for Alzheimer's disease: towards clinical implementation

The Lancet Neurology, Journal Year: 2021, Volume and Issue: 21(1), P. 66 - 77

Published: Nov. 25, 2021

Language: Английский

---

Performance of plasma phosphorylated tau 181 and 217 in the community

Nature Medicine, Journal Year: 2022, Volume and Issue: 28(7), P. 1398 - 1405

Published: May 26, 2022

Language: Английский

---

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease

Alzheimer s Research & Therapy, Journal Year: 2018, Volume and Issue: 10(1)

Published: July 28, 2018

A growing body of evidence suggests that the plasma concentration neurofilament light chain (NfL) might be considered a biomarker for screening neurodegeneration in Alzheimer's disease (AD). With single molecule array method (Simoa, Quanterix), NfL concentrations were measured 99 subjects with AD at stage mild cognitive impairment (MCI-AD; n = 25) or early dementia (ADD; 33), and nondemented controls (n 41); all patients, clinical diagnoses accordance results four core cerebrospinal fluid (CSF) biomarkers (amyloid β (Aβ)1–42, Aβ42/40, Tau, pTau181), interpreted according to Erlangen Score algorithm. The influence preanalytical storage procedures on was tested samples exposed six different conditions. significantly increased more than one freezing/thawing cycle, those stored 5 days room temperature 4 °C. Compared control group (22.0 ± 12.4 pg/mL), unadjusted highly higher MCI-AD (38.1 15.9 pg/mL, p < 0.005) even further elevated ADD (49.1 28.4 pg/mL; 0.001). significant association between age (ρ 0.65, 0.001) observed; after correcting age, difference remained (p 0.044). At cutoff value 25.7 unconditional sensitivity, specificity, accuracy 0.84, 0.78, 0.82, respectively. Unadjusted correlation Mini Mental State Examination (MMSE) across patients moderate but (r −0.49, We observed an overall CSF biomarkers, this not within diagnostic groups. This study confirms compared controls.

Language: Английский

---

Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry

The World Journal of Biological Psychiatry, Journal Year: 2017, Volume and Issue: 19(4), P. 244 - 328

Published: Oct. 27, 2017

In the 12 years since publication of first Consensus Paper WFSBP on biomarkers neurodegenerative dementias, enormous advancement has taken place in field, and Task Force takes now opportunity to extend update original paper. New concepts Alzheimer's disease (AD) conceptual interactions between AD dementia due were developed, resulting two sets for diagnostic/research criteria. Procedures pre-analytical sample handling, biobanking, analyses post-analytical interpretation results intensively studied optimised. A global quality control project was introduced evaluate monitor inter-centre variability measurements with goal harmonisation results. Contexts use how approach candidate biological specimens other than cerebrospinal fluid (CSF), e.g. blood, precisely defined. Important development achieved neuroimaging techniques, including studies comparing amyloid-β positron emission tomography fluid-based modalities. Similarly, research laboratory technologies, such as ultra-sensitive methods, raises our hopes further improve analytical diagnostic accuracy classic novel biomarkers. Synergistically, clinical trials anti-dementia therapies energises motivates efforts find optimise most reliable early Finally, published addressing potential cost-effectiveness biomarkers-based diagnosis disorders.

Language: Английский

---

Blood-based molecular biomarkers for Alzheimer’s disease

Molecular Brain, Journal Year: 2019, Volume and Issue: 12(1)

Published: March 28, 2019

A major barrier to the effective conduct of clinical trials new drug candidates against Alzheimer's disease (AD) and identifying patients for receiving future disease-modifying treatments is limited capacity current health system find diagnose with early AD pathology. This may be related in part systems select those people likely have pathology order confirm diagnosis available cerebrospinal fluid imaging biomarkers at memory clinics. In narrative review, we summarize literature on candidate blood tests that could implemented primary care settings used identification individuals increased risk pathology, who referred potential inclusion or approved following additional testing. We give an updated account blood-based biomarker panels AD-related brain changes. Our analysis centres been replicated more than one study discusses need further studies achieve goal a care-based screening algorithm AD.

Language: Английский

---